In 2012 an inducible mouse model of NRAS mutant melanoma and network modelling established the in-vivo therapeutic syngeristic efficacy of targeted inhibition of CDK4 and MEK to decrease melanoma survival and proliferation [46]. Here, CDK4 is linked to melanoma.